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1°) GENOTYPIC ANALYSES OF CYCLOSPORINE-ASSOCIATED LYMPHOPROLIFERATIONS 
We recently reported a series of 17 allograft recipients who 
developed lymphoproliferative disorders while on a cycJospo· 
rine-steroid·containing regimen (1). The results indicated good 
patient survival with conservative therapy, (i.e., control of local 
complications and reduction of immunosuppression), regardless 
of whether the lesions were monoclonal or polyclonal. Clonal 
designation in that report was based on immunoperoxidase 
staining of formalin-fixed, paraffin-embedded tissues. Appro-
priate caution was recommended regarding noncritical accept-
ance of clonal status, due to the known shortcomings of the 
immunoperoxidase technique (J -3). 
Tissue from several cases has been analyzed for immuno-
globulin gene rearrangements (J. S. and M. 1. C.), using pub-
lished techniques (4) (Table 1). Four of five cases so studied 
have shown evidence of monoclonality, supporting our original 
interpretation. Indeed, one case phenotypically categorized by 
us as polyclonal (No.9) on the basis of a kappa:lambda ratio 
of 1.5: 1 was shown to be monoclonal by gene analysis. Because 
the majority of cells were unstained by immunoperoxidase 
methods. the gene rearrangement results are consistent with a 
true monoclonal tumor or a monoclonal proliferation arising in 
a polyclonal background. 
Three separate synchronous tumors from patient 12 showed 
different monoclonal patterns of rearrangements, suggesting 
either independent primary tumors or possible subclones de· 
rived from one original clone (5). Tissue from patient 16 
exhibited clonal rearrangements on Iv of kappa light chains . 
This verifies the monoclonal nature of the lesion and agrees 
with the original kappa designation of the tumor. Multiple 
bands in patient 17, originally designated as polyclonal, may 
TABLE I. Immunoglobulin gene rearrangement studies in transplant 
recipients with lymphoproliferative disease" 
Pt. 1'\0. H K L Interpretation 
6 R R R Monoclonal B cell 
9 R R R Monoclonal B cell 
12 W) R D R Monoclonal B cell 
12 (G) R R G Monoclonal B cell 
12 ()) R D R Monoclonal B cell 
16 R R G Monoclonal B cell 
17 R M G Multiclonal 
"H: heavy chain region; K: kappa region; L: Lambda regIOn; R: 
rearranged: D: deleted; G: germline; M: multiple; (F, G, I) = different 
gastrointestinal nodules. 
instead indicate the presence of a small number of proliferating 
clones in the lesions. 
Patients 6 and 12 are alive and well at 39 and 28 months, 
respectively, following tumor diagnosis. Both underwent sur. 
gical intervention and a reduction of immunosuppression. Pa-
tient 12 received no chemotherapy, whereas patient 6, diag-
nosed in 1982, did. Patient 17 died 17 months following tumor 
diagnosis. Death was consequent to a second heart· lung trans· 
plant for pulmonary difficulties. No tumor was found at au-
topsy. Patients 9 and 16 died a short time after diagnosis, as 
previously reported. 
The correlation between the clinical results and gene re-
arrangement studies encourages us to employ a conservative 
approach based on operation followed by reduced immunmo· 
suppression in the management of these tumors, even when 
monoclonality is demonstrated. However, at the same time, we 
recognize that significant differences of disease manifestation 
among different series may exist, as noted by Hanto et a1. (3). 
These investigators pointed out the high frequency of gastroin-
testinal lymphomas in our series (3), This contrasts with the 
frequent central nervous system involvement seen in their cases 
(6). The reasons for these differences are not clear, but may 
reflect differences in the immunosuppressive regimens used. 
Only 1 of their 19 reported patients received cyclosporine (6), 
in contrast to all in our series (1). It thus appears prudent to 
apply our findings with this caveat in mind, until differences 
can be reconciied and generalizations established. 
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EFFI . OF HYDERGINE ON CYCLOSPORINE-INDUCED NEPHROTOXICITY IN A RAT KIDNEY 
TRA:\SPLANTATION MODEL 
Cyclosporine (CsA)· has now been established as a most 
effective immunosuppressive agent in man and various animal 
models (J, 2). Apart from one exception in living-related donor 
renlll transplantation in diabetics (3), it has never been shown 
to be inferior, but is mostly superior, to conventional immu-
no;:'" "ression, when considering patient and graft survival. 
H, 'r several side effects have also been reported during 
r ,,-, erapy-such as hepatotoxicity, nephrotoxicity, effects 
on the central nervous system (CNS), resulting in convulsion 
and tremor, anorexia, hirsutism, gum hypertrophy, and in-
creased renin-angiotensin-aldosterone system (RAAS) activity 
1.J.51. 
CsA associated nephrotoxicity, being reported ever since the 
first study of the use of CsA in clinical renal transplantation 
161. is one of the most frequently occurring adverse effects of 
(",\ ,l·,·rapy. This nephrotoxicity appears to be reversible and 
d, ·ndent. On the basis of renal scans, CsA nephrotox-
Il; been attributed to acute tubular necrosis (7). Other 
~trnicI in rats have proposed that the nephrotoxicity.is caused 
hy a glomerular rather than a tubular mechanism (8). However, 
absence of any histological change in patients manifesting 
nephrotoxicity has also been reported (9). The correlation of 
morphological changes with nephrotoxicity is still not clear. 
\. arious attempts have been made to modify CsA-associated 
nE'phrotoxicity. Caine (10) suggested induction of forced di-
II r£' .:, \ it h fl uid and mannitol and delay of CsA administration 
u; hlishment of posttransplant diuresis. However, others 
,j Ilat this early posttransplantation complication was 
thl"lt of acute rejection rather than CsA nephrotoxicity 
and that it reacted well to steroid therapy (J 1). Unsuccessful 
attempts in transplant patients have been made to correct 
nephrotoxicity by means of dopamine infusions (12). Attempts 
to accelerate CsA metabolism using hepatic Cyt-P450 enzyme-
c<,mplex inducer, have been made in rats, resulting in reduced 
nephrotoxicity (13), Generally the strategy has been to reduce 
th~ ED~A dose or convert to conventional therapy-however, 
th'lsures may be followed by rejection of the graft (14). 
., been reported to increase sympathetic nerve activity 
lIi , .taneous hypertensive rats (5). This was indicated as 
leaelm!: to stimulation of the RAAS-system, as well as release 
(,f angiotensin II, and inhibition of renal prostaglandin synthe-
'IS. Prevention of CsA nephrotoxicity in rats with prut;taglan-
dins has been described by Makowka et al. (5). 
• Abbreviations used: BUN. blood urea nitrogen; eNS. central nerv-
"U, p~DstfDm: esA. cycJosporine; GFR, glomerular filtration rate: RAAS, 
r\·nin-anl:lotensin·aldosterone system; RGFR, relative GFR. 
Hydergine is a partial al and a2 acirenoceptor agonist that 
also has a stimulating effect on dopamine and an antagonistic 
activity on the 5HT receptor. Considering these properties of 
Hydergine, it has been suggested that it might interfere with 
the proposed mechanism of CsA-indu~ed nephrotoxicity (5). 
The present study, using a rat kidney allograft model, was 
undertaken to investigate whether Hydergine could prevent or 
offer partial protection from CsA-induced nephrotoxicity. 
Male BN (RTln) and WAG (RTlU) rats, weighing about 250 
g were used as kidney graft donors and recipients, respectively. 
Kidney transplantations in the BN-to-WAG combination were 
performed using microsurgical techniques, as described earlier 
(16). Bilateral nephrectomy was done at the time of operation. 
CsA, diluted in olive oil, was administered i.m. in a volume of 
0.2 ml. Hydergine (Sandoz) was administered i.p. in doses of 
0.5 mg/kg/48 hr. Glomerular filtration Rates (GFR) were meas-
ured as clearances of ~fCr-ethylenediaminotetraacetate using a 
method described in detail earlier (17). The relative glomerular 
filtration rate (RGFR; expressed as a percentage of normal 
GFR) was calculated by considering the GFR of WAG rats with 
both kidneys intact to possess an RGFR of 100% (17). 
Serum creatinine (normal value 43±4 Ilmol/L), blood urea 
nitrogen (BUN, normal value 8.6±1.1 mmol/L), and serum Na 
and K values, were determined at regular intervals using stand-
ard analytical procedures . 
The experimental design was as follows: Kidney transplan-
tations in the BN -to-WAG combination were performed and 
the rats divided into two groups. One group was treated with 
CsA 15 mg/kg/48 hr from the day of transplantation for a 
period of 35 days (group 1, n=8). At the end of this period 
GFRs were determined. From day 42 onward these rats were 
treated with esA 100 mg/kg/48 hr for a period of 21-28 days 
(group la). At the end of this period GFRs were determined 
again. A second group of kidney-allografted rats underwent the 
same treatment with CsA as the group above, except that they 
additionally received Hydergine, from the day of transplanta-
tion, 0.5 mg/kg/48 hr (groups 2 and 2a, n=8). All through this 
treatment period serum creatinine, BUN, Na, K, and body 
weight were determined regularly. The results were analyzed 
statistically by using the Student's t test. 
In Table 1 the RGFRs of the groups treated with CsA and 
CsA + HyderginE' are given. At the end of the first 35 days of 
treatment with low doses of esA, the mean RGFRs of the CsA 
(group 1) and CsA + Hydergine groups (group 2) were 34.4± 
8.2 and 28.2±16./. respectively. This difference is not statisti-
cally significant. After completion of the treatment with a dose 
